Business Wire - December 5, 2007
The Institute will develop an immunology, microbiology and vaccine research laboratory platform to encourage cooperation between scientists working in the field of HIV, malaria, tuberculosis, influenza and cancer vaccine development in Switzerland, from fundamental to clinical researchers. Vaccines against hepatitis C, Dengue fever and other infectious agents may be developed at a later date.
The Institute will initially be based on a partnership between the following Swiss institutions:
* The Centre Hospitalier Universitaire Vaudois (CHUV) and the Faculty of Biology and Medicine (FBM) of the University of Lausanne (UNIL),
* the Ecole Polytechnique Federale de Lausanne (EPFL),
* the Institute for Biomedical Research in Bellinzona (IRB),
* and the Ludwig Institute for Cancer Research, Lausanne branch in Epalinges (LICR).
These four institutions have a strong tradition in the fields of immunology, virology, and vaccines against HIV/AIDS, malaria, tuberculosis and cancer. The new Institute will further seek collaboration with other Swiss institutions.
The new Institute also aims to train new generations of scientists in the field of vaccines, by creating several new research groups. The Institute will work with the most prominent public and private organizations involved in vaccine development and will also encourage cooperation with industrial partners.
The role of each partner
The Swiss Institute for Vaccine Research will initially be based on four partner institutions, selected for their scientific competence and clinical or laboratory infrastructures.
The CHUV will conduct the translational and immunology programmes for the evaluation of immune responses induced by a vaccine. The CHUV will also make available its clinical trial infrastructure.
The EPFL will conduct the fundamental research programme in virology, microbiology and vectorology. The ease of access to robotics and microtechnics will be of prime importance for the development of new high flow and automated immunology tests. The EPFL will also make available the infrastructures for proteomics, microscopic and biomedical imaging, protein production, genomics, and high flow biomolecular screening.
The IRB will conduct the fundamental research programme in immunology with, as its main objective, the characterization of T cell memory and the study of the mechanisms causing T cell responses.
The LICR will conduct a fundamental research programme in immunology aimed at characterizing specific tumour responses generated by vaccination.
The launch
The launch of the Swiss Institute for Vaccine Research will take place on December 5, 2007, at 17 :00 CET, in Lausanne, Switzerland, in the presence of the Swiss Secretary of State for Education and Research, Charles Kleiber, representatives of the Bill & Melinda Gates Foundation and the World Health Organization (WHO) as well as leading US specialists in HIV/AIDS research.
Contacts
Genevensis Healthcare Communications | for Swiss Institute for Vaccine Research Daniele Letore-Castle | Tel. +41 22 779 0620 | Mob: +41 79 202 6667 | Mail: info@genevensis.com
071205
BW071204
Copyright © 2007 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .